Introduction
Proton pump inhibitors (PPIs) are indicated for treatment of a range of acid-related gastrointestinal disorders, including gastro-oesophageal reflux disease (GORD), dyspepsia and peptic ulcer disease [1] . Prevalence of PPI use has increased significantly, particularly among the older population. Utilization of PPIs increased more than 13-fold in Australia between 1995 and 2006, with the majority dispensed to patients aged 80 years and over [2] . Similarly high rates of PPI use have been observed internationally. Twenty one percent of Canadians aged 65 years and over received subsidized PPI therapy during 2006-2007 [3] , and 36% of older people in New Zealand received a PPI in 2013 [4] .
Evidence suggests that up to 80% of patients diagnosed with GORD can be managed with a step-down approach to therapy [5] ; that is, reducing the dose to the lowest effective dose which controls the symptoms. Despite this, the majority of PPIs dispensed are standard strength products [2] and there is evidence that therapy is continued for prolonged periods. An Australian study examining the duration of PPI therapy among older patients with GORD demonstrated that only one third of patients on the standard or higher strength products reduced the PPI dose or discontinued treatment within two months as recommended by national guidelines [6] . One third of the cohort were still receiving standard or high dose therapy after one year [6] . In a USbased study, only 12% of patients with GORD who were initiated on a high strength PPI had stepped-down to a lower dose or discontinued therapy within two years of initiation [7] .
Although PPIs are considered to be relatively safe, serious adverse events have been reported. Treatment with PPIs has been associated with increased risk of pneumonia, fracture and enteric infection [8] [9] [10] [11] [12] [13] . Hypomagnesaemia, vitamin B12 deficiency and acute interstitial nephritis have also been reported [1] . Current guidelines recommend reducing the PPI dose, adopting intermittent use or trialling cessation to maintain symptom control and reduce the risk of adverse events [14] .
To date, interventions aiming to improve the use of PPIs in the primary care setting have been directed towards either consumers, general medical practitioners (GPs) or pharmacists, but not multiple stakeholders, and these studies report mixed results. A systematic review of randomized controlled trials and cohort studies published between 1995 and 2004 included six studies which assessed the impact of educational interventions to reduce the use of acid suppressive medicines in the primary care setting [15] . Of these, the two randomized controlled trials assessing patient-based educational interventions demonstrated a reduction in the use of acid suppressive medicines, while only one of the four trials assessing the impact of educational interventions targeting GPs reported reduced use [15] . Subsequent studies assessing the impact of primary care interventions on PPI use also report conflicting results. Evaluation of several multifaceted interventions targeting GPs in the Netherlands showed that provision of educational materials, patient-specific feedback and financial incentives to GPs did not reduce use of PPIs and H 2 receptor antagonists, and while the addition of a GP telephone support service reduced acid-suppressant medicine use, supplementary academic detailing had no impact on use [16, 17] . Use of PPIs also remained unchanged after a UK-based educational intervention targeting GPs [18] and another targeting primary care patients [19] . Although some interventions to improve the use of PPIs in the community setting have resulted in an immediate impact, sustained behaviour change has not been achieved. A randomized trial involving 185 community pharmacies in Australia assessed the use of a dispensing prompt to alert pharmacists to discuss step-down therapy with patients taking high dose PPIs [20] . There was a 10-fold increase in pharmacist intervention rates in comparison to controls, however the number of interventions each week had declined to baseline by the end of the 12 week study period [20] . Similarly, another randomized trial demonstrated a three-fold increase in PPI withdrawal or dose reduction at 12 weeks compared to controls, however the effect was not sustained at 20 weeks post-intervention [21] .
Several national programmes directed at both patients and health care professionals have been implemented in Australia over the last decade with the aim of improving PPI use. The Veterans' Medicines Advice and Therapeutics Education Services (Veterans' MATES) programme [22] and NPS MedicineWise (formerly known as the National Prescribing Service) [23] (Fig. 1) . The programmes were designed to be complementary and all interventions had the same overarching aim to improve the use of PPIs by encouraging clinicians to consider step-down strategies for patients receiving ongoing PPI therapy. The aim of this study was to evaluate the impact of these national, multifaceted, quality improvement programmes on overall PPI use and use of low strength PPIs by older Australians.
Methods

Description of the interventions
Veterans' MATES is a national quality improvement programme funded by the Australian Government Department of Veterans' Affairs (DVA) which targets all eligible Australian veterans and dependents. The programme, which is underpinned by behavioural theory and strong stakeholder engagement, has been described in detail elsewhere [22] . The Veterans' MATES interventions to improve PPI use were conducted in 2006 and 2012 and each intervention targeted veterans who were regularly dispensed a PPI. The number of veterans and health professionals targeted in each Veterans' MATES intervention is shown in Table 1 . Patients who were targeted in the first Veterans' MATES intervention in 2006 were eligible to be targeted in the following Veterans' MATES intervention in 2012 if they were still dispensed a PPI on a regular basis. Targeted patients were mailed a consumer-focused educational brochure outlining the role of PPI treatment and the need for regular review of therapy. All GPs providing care for veterans taking a PPI were mailed detailed feedback listing each of their patients receiving ongoing PPI therapy together with tailored educational information encouraging a step down approach for managing GORD symptoms. The educational information was also mailed to all community pharmacies, and pharmacists accredited to perform home medicines reviews for people living in the community and residential medication management reviews for residents in aged care facilities. Directors of nursing in residential aged care facilities (n = 2602) were also mailed the educational information during the second intervention in August 2012 as high use of PPIs had been observed in this setting between the intervention periods [24] . All PPI materials were developed in consultation with a multidisciplinary clinical reference group and were peer reviewed by relevant stakeholders. The entire process was overseen by a national editorial committee and a national call centre provided post-implementation support services [22] .
NPS MedicineWise is a national, not-for-profit organization which aims to improve medicines use in Australia and conducts quality improvement activities targeting all Australian consumers, GPs and pharmacists. NPS MedicineWise was established as the key agency to support Australia's National Strategy for Quality Use of Medicines. NPS MedicineWise initiatives are underpinned by a social marketing framework. An expert advisory group is used to determine the key messages for each initiative and materials developed are peer reviewed [23] . The key messages for the NPS MedicineWise PPI programmes run in 2004, 2006 and 2009 were delivered using a combination of active and passive strategies which included provision of written educational materials and case studies for clinicians to complete, academic detailing, GP audit and feedback, peer group meetings with opinion leaders and consumer educational resources [23] . NPS MedicineWise is a collaborator within the Veterans' MATES programme to ensure interventions conducted by each agency are complementary and that key messages are consistent. Representatives from NPS MedicineWise are also involved in the Veterans' MATES clinical reference group and the national editorial committee.
Evaluation of the interventions
We conducted a retrospective observational study using data from DVA's health claims database. Veterans who have served in Australia's defence force, war widows, war widowers and other dependents may be eligible for DVA-subsidized health benefits [25] . DVA maintain a database which contains details of health services for eligible clients for which DVA pays a subsidy. In December 2013, the DVA treatment population consisted of 221 635 persons living in the community or residing in aged care facilities, in all regions of Australia, and the majority (83%) were aged 70 years and over [26] .
The DVA database includes details for all DVA-subsidized health claims for hospitalizations, primary care consultations, allied health visits, prescription medicines and residential aged care admissions. Claims for medicines dispensed to DVA clients are coded in the database using the World Health Organisation Anatomic and Therapeutic Chemical (ATC) classification and the Schedule of Pharmaceutical Benefits item codes. The database also contains a client file which includes the name, date of birth, address, gender and date of death for all persons receiving DVA-subsidized health services.
Prescription claims between 1 January 2003 and 31 December 2013 were assessed to determine the monthly rate of PPI use among the veteran population. This provided sufficient data points [27] to assess trends in PPI use before the first NPS intervention in April 2004, and determine trends in PPI use after the final Veterans' MATES intervention in August 2012. The monthly rate of PPI use was determined by dividing the number of patients receiving any PPI (identified by ATC code A02BC) in the month by the total number of veterans alive in the month. We also assessed the monthly rate of use of low strength PPIs among all PPI users, defined as the number of patients receiving a low strength PPI in the month divided by the total number of patients receiving a PPI that month. Low strength PPIs were defined as omeprazole 10 mg, pantoprazole 20 mg, rabeprazole 10 mg and lansoprazole 15 mg preparations. Standard or high strength products included esomeprazole 20 mg, Figure 1 Steps undertaken to improve PPI use in Australia.
esomeprazole 40 mg, omeprazole 20 mg, pantoprazole 40 mg, rabeprazole 20 mg and lansoprazole 30 mg. Esomeprazole 20 mg was classified as a standard strength PPI in accordance with educational information developed by NPS MedicineWise and recommendations contained within Australia's national therapeutic guideline on the management of gastrointestinal diseases [14] . These peer-reviewed information sources consider the existing literature and leading expert opinion when formulating recommendations to guide decisionmaking by Australian health professionals. Prescription duration is not available in the dataset; however, standard subsidized supply is for 30 days. Further, 75% of the population received another PPI supply within 36 days, thus, 36 days from the date of dispensing was used as the prescription duration.
Statistical analysis
Interrupted time series modelling using segmented regression with change points at the time of each intervention was used to assess the effect of each intervention on the rate of PPI use. Interrupted time series analyses are commonly applied to pharmaceutical claims data to determine whether an intervention or change in health policy has led to a change in medication use [27] . Importantly, this method can be used to assess changes in medication use after multiple change points, which means the cumulative effect of multiple interventions at different times can be assessed, while also accounting for potential biases such as seasonal variation in medication supply [27] .
The models included terms to estimate (a) the baseline trend, defined as the month-to-month change in the rate of PPI use before the first intervention in April 2004; (b) the change in level after each intervention, defined as the jump or drop in the rate of PPI use immediately after an intervention; (c) the change in trend after each intervention, defined as a change in the slope of the post-intervention line in comparison to the pre-intervention line; and (d) interaction terms (time*change in trend). We also controlled for nonstationarity, seasonality and any autocorrelation in the time series. Stepwise backward elimination was used to determine the model of best fit. Output from the regression models, including the trend line without interventions (the estimated trend if the interventions had not occurred; i.e. with no intervention effects included in the model), the predicted rate of PPI use when the intervention effects were included in the model as well as the trend line, together with the actual rate of PPI use observed per 1000 people included in the study, was plotted for each month during the study period to provide a visual representation of the model. Consistent with previous interrupted time series analyses [28] , the combined effect of the Veterans MATES and NPS MedicineWise interventions on the rate of PPI use was expressed as (1) the average month-to-month change (%) in the trend line with interventions and the trend line without interventions after the final change point in August 2012, calculated as the ratio of the model-estimated values in each month to the values from the previous month; (2) the absolute combined effect, expressed as the absolute difference between the model-estimated values for PPI use at 12 months after the final intervention and values estimated as if the intervention had not occurred (i.e. the trend line without interventions); and (3) the relative combined effect, expressed as a percentage decrease in the rate of PPI use or a percentage increase in the rate of low strength PPI use among all PPI users at 12 months after the final intervention.
Data were analysed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
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Results There were 64 610 people dispensed a PPI in January 2003, of which 58% were men and the median patient age was 79 (interquartile range (IQR) 76-83) years. Eight percent of PPI users lived in a residential aged care facility. The median number of unique medicines dispensed in the 12 months prior to study entry was 13 (IQR 9-19).
PPIs were dispensed to 70 688 people in December 2013. The median patient age was 87 (IQR 79-90) years, 47% were male, and 16% resided in an aged care facility. The median number of unique medicines dispensed in the previous year was 13 .
In January 2003, the most commonly used PPIs were omeprazole (55%), pantoprazole (21%) and esomeprazole (12%). Esomeprazole was the most commonly dispensed PPI in December 2013 (38%), followed by pantoprazole (29%) and omeprazole (16%).
Time series analysis showed all four interventions had a significant effect on overall PPI use (Supplementary File, Table S1 ). Use of PPIs was increasing at the start of the study period (Fig. 2) . In Table 2 ). The combined effect of all four interventions was a 21% relative decrease in PPI use 12 months after the final intervention (Table 2) .
Trends in the proportion of patients receiving a low strength among all PPI users are presented in Fig. 3 . The monthly rate of use tripled over the study period, increasing from 1.8% in January 2003 to 5.3% in December 2013. Time series analysis showed significant effect of all four interventions (Table 2, Supplementary File, Table S2 ). Overall, their combined effect led to a 42% relative increase in the use of low strength PPIs 12 months after the final intervention (Table 2) .
Discussion
The results of this study show the Veterans' MATES and NPS MedicineWise interventions were successful, leading to improvements in PPI use at the national level. The NPS MedicineWise intervention in April 2004 slowed the rate of increase in PPI use among older Australians. Subsequent interventions in June 2006 and May 2009 built on the effect of earlier interventions, further slowing the rate of increase in PPI use, with the final Veterans' MATES intervention in August 2012 leading to a reduction in PPI use. Use of low-strength products was low, however, this study also showed a three-fold increase in the proportion of patients receiving a low strength PPI during the study period, with significant increases in low strength PPI use following all four interventions.
While interventions to improve care may show initial success, sustaining change can be challenging. Previous PPI interventions directed at GPs, pharmacists or consumers in the primary care setting have had mixed success and did not achieve sustained practice change. A recent review of health care interventions encompassing audit and feedback showed that few interventions are grounded in behavioural theory, nor do they incorporate successive plan-do-study-act cycles, with regular feedback that builds on information delivered in previous cycles, even though evidence suggests these characteristics are related to success [29] . In contrast, the Veterans' MATES and NPS MedicineWise programmes are underpinned by behavioural theory and strong stakeholder engagement, with interventions targeting consumers, GPs, pharmacists and residential aged care facilities nationally. Our study results highlight how repeating the same key messages to multiple stakeholders in different interventions, at different time points, with each intervention building on the previous intervention, can lead to sustained practice change at the national level. These findings are consistent with behavioural theories which suggest that repetition and reinforcement of the same message can lead to sustained behaviour change [30] and studies in other health care settings which demonstrate that regular monitoring and feedback can improve care [31, 32] . The benefits of this approach should be considered when planning quality improvement interventions for similar populations. Australia has several other national resources that support the key messages provided by the NPS MedicineWise and Veterans' MATES interventions. The step-down approach to PPI therapy was also addressed in Australia's national formulary [1] and national therapeutic guidelines [14] . The long-term management of patients taking PPI therapy was also addressed in Australia's national therapeutics bulletin (Australian Prescriber) in 2008, while adverse events resulting from PPI therapy were highlighted in several bulletins released by Australia's Therapeutic Goods Administration in 2003, 2009 and 2011. It is likely that these resources reinforced the messages in the interventions, however given the temporal relationship between each of the Veterans' MATES and NPS MedicineWise initiatives and the changes in PPI use, it is the interventions that appeared to drive the practice changes demonstrated in our study.
The level of PPI use observed in this older population is similar to that observed in other international studies [3, 4] . However, little is known about changes in the use of lower strength PPI therapy in other settings. In a Canadian study assessing PPI use among patients aged 65 years and over, the proportion of patients taking a low daily dose (where the average daily dose was ≤0.5 times the PPI defined daily dose) decreased from 13.6% in 2001-2002 to 10.3% in 2006-2007 [3] . In our study, more than 5% of older patients treated with PPIs were treated with a low strength product each month by the end of the study period. However, we assessed trends in the strength of the PPI dispensed in order to assess the impact of each initiative rather than estimating changes in the average daily dose over time.
In this study, 31% of older Australians received a PPI in December 2013, which suggests there is scope to further improve use of PPIs among older Australians. Despite this, the Veterans' MATES and NPS MedicineWise interventions are likely to have led to changes in PPI use for a significant number of people, particularly as Australia was the highest consumer of acid suppressive medicines in comparison to other Organisation for Economic Co-operation and Development (OECD) countries at the start of the study period [33] . [34, 35] . The interrupted time series models used in the NPS MedicineWise analyses were adjusted for medicine price and policy changes during the study period. As we were unable to account for switches to intermittent PPI use or cessation of therapy in the present study, our findings are likely to underestimate the true impact of each PPI programme in the older Australian population.
The strengths of this study include the ability to track changes in the use PPIs at the national level, for a large sample of older Australians. We expect capture of all PPI use in the primary care setting is likely as these medicines are subsidized for use among the study population. Although selected lower strength PPIs could be obtained from a pharmacy without a prescription from October 2008 onwards, this is unlikely to have impacted on trends in this study as these medicines are only available in small quantities and unlike prescription PPIs, over the counter purchases are not subsidized. The Australian veteran population which was targeted in the Veterans' MATES interventions has similar rates of medicine use and medical consultations in comparison to other Australians of the same age [36] , and therefore we would expect the NPS MedicineWise programme, which targeted all Australians using PPIs, to have achieved a similar impact among other older Australians.
In this study, we estimated the duration of each prescription as the time within which 75% of patients had their PPI prescription refilled (36 days) as we could not determine actual PPI consumption. Although this approach is suitable for determining exposure to medicines taken on a regular basis [37] , exposure misclassification is possible as patients may have used PPIs for short periods or 'stepped down' to use only when needed. Another limitation of this study is that we were unable to assess appropriateness of PPI use among those dispensed therapy. The impact on patient health outcomes following a reduction in PPI use was not examined; however, the harms associated with PPI therapy have been previously demonstrated in this older Australian population [9, 10, 13] .
A further limitation is that we were unable to determine whether the health professionals providing care for veterans taking a PPI actually received or accessed information from NPS MedicineWise during their PPI interventions. However, veterans and their dependents receive care from the same health care professionals as nonveterans, and more than one third of all Australian GPs participated in the NPS MedicineWise interventions targeting PPI use [34, 35] .
In conclusion, improvements in PPI use were observed among older Australians following a series of national, multifaceted, quality improvement programmes directed at both consumers and health care professionals which encouraged a review of the need for PPI therapy. These results suggest that interventions to improve medicine use in this area should engage multiple stakeholders and regularly repeat key messages in order to sustain practice change.
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